Interviews

Opioids have been used for hundreds of years to treat restless leg syndrome (RLS), but there is currently a registry to understand the long-term effectiveness of opioids to treat RLS , said John Winkelman, MD, PhD, medical director, sleep disorders clinical research program, Massachusetts General Hospital.

Kim A. Reiss, MD, assistant program director of the Hematology/Oncology Fellowship Program and assistant professor of medicine at the Hospital of the University of Pennsylvania, discusses pancreatic cancer research she presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Joel W. Neal, MD, PhD, associate professor, Division of Oncology, Stanford Cancer Institute, is lead investigator on the COSMIC-021 trial, which is investigating cabozantinib plus atezolizumab vs cabozantinib alone in patients with advanced non–small cell lung cancer (NSCLC) as a possible second-line treatment beyond chemotherapy.

Gary Owens, MD, president of Gary Owens Associates, explains the importance of shared decision making and patient-centered care in pulmonary arterial hypertension (PAH).

Thanos Zomas, MD, global medical lead, Lymphoma and Leukemia, and global medical lead, Adcetris Program, at Takeda Oncology discusses updated results from the ECHELON-1 study.

David R. Penberthy, MD, MBA, is medical director, Radiation Oncology, Bon Secours-Southside Medical Center in Petersburg, Virginia, and president of the Association of Community Cancer Centers for the 2022-2023 term.

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, discusses his partnership with Sema4 and LabCorp and their joint goal to advance whole-exome sequencing (WES) for targeted oncology treatment.

Enrique Ocio, MD, PhD, hematology department head, Marqués de Valdecilla University Hospital, Santander, Spain, discusses phase 1b trial results for subcutaneous (sub-Q) vs intravenous isatuximab, both formulations administered in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (RRMM).

Michael Ciarametaro, MBA, vice president of research at the National Pharmaceutical Council (NPC), explains the ways that the gene therapy market is working to address concerns regarding contractual riders for value-based contracts for expensive therapies.

Randall A. Oyer, MD, medical director, oncology, and medical director, Cancer Risk Evaluation Program, Lancaster General Health, and clinical professor of cancer biology at Penn Medicine, discusses the recent American Society of Clinical Oncology/Association of Community Cancer Centers recommendations for improving diversity in clinical trials.

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, talks with us ahead of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Susan Redline, MD, MPH, professor of sleep medicine and epidemiology, Harvard T.H. Chan School of Public Health, gives a preview of her SLEEP 2022 keynote and discusses her 30 years of sleep epidemiology advocacy.

Will Nutland, DrPH, is cofounder of PrEPster, honorary assistant professor at the London School of Hygiene and Tropical Medicine, and an activist.

Allogeneic, or off-the-shelf, chimeric antigen receptor (CAR) T-cell therapies will bring new logistical challenges, said Aklilu Tedla, vice president, insights and engagement, regulatory science, cell and gene, Cardinal Health.

On this episode of Managed Care Cast, Hui Zheng, PhD, discusses his recent research on the association between childhood income inequality and declining adult health.

Leaders from Banner|Aetna discuss the joint venture that has grown to 375,000 members since it launched in 2017 to offer health plans to employers in Arizona.

Leaders from Banner|Aetna discuss the joint venture that has grown to 375,000 members since it launched in 2017 to offer health plans to employers in Arizona.

Leaders from Banner|Aetna discuss the joint venture that has grown to 375,000 members since it launched in 2017 to offer health plans to employers in Arizona.

Leaders from Banner|Aetna discuss the joint venture that has grown to 375,000 members since it launched in 2017 to offer health plans to employers in Arizona.

The organizations that can take on 2-sided risk are usually bigger and that’s not always better for health care, said Jayson Slotnik, partner, Health Policy Strategies, Inc.

Alignment of incentives in the United States do not always support the use of biosimilars or other lower-cost alternatives, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.

Jessica Brooks, MPM, president and chief executive officer, Pittsburgh Business Group on Health, spoke on the core themes of her keynote address related to diversity, equity, and inclusion at the 2022 Greater Philadelphia Business Coalition on Health annual conference.

Many payers are not familiar with digital therapeutics, indicating the need for better education among payers, said Jayne Hornung, chief clinical officer, pharmacy, MMIT.

Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, describes the lasting equity concerns regarding the use of health technology assessments (HTAs) for women.

Gary Owens, MD, president of Gary Owens Associates, describes mechanisms, trials of treatments in the works for pulmonary arterial hypertension (PAH).

Steven Yeh, MD, professor of ophthalmology at the Truhlsen Eye Institute at the University of Nebraska Medical Center, talks about what he sees in the future of suprachoroidal administration and other unmet needs in ophthalmology.

Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, discusses 3 ways in which the FDA can provide, and has provided, assistance on the capture of real-word data (RWD) in electronic medical records.

The logistics for storing chimeric antigen receptor (CAR) T-cell therapies remain a challenge, said Joel Wayment, vice president of operations for 3PL Services, Cardinal Health.

At Digestive Disease Week 2022, John M. DeWitt, MD, professor of medicine, Indiana University Health, explains his findings on the diagnosis and management of achalasia in 2022 and how the COVID-19 pandemic affected these trends.

At Digestive Disease Week 2022, Sravanthi Parasa, MD, gastroenterologist at Swedish Gastroenterology, talks about how artificial intelligence (AI) is used in gastroenterology and what challenges it may pose for clinicians.